ROYAL OAK, Mich.--(BUSINESS WIRE)--OncoCell MDx™, an immunogenomics platform company specializing in the delivery of novel, noninvasive molecular diagnostic assays, today announced the appointment of Christopher Thibodeau as its Chief Operating Officer. He joins Mark McDonough, recently appointed as OncoCell’s President, Chief Executive Officer and member of the Board of Directors, in strengthening the company’s executive leadership team.
"OncoCell continues to build a world class management team as we develop our pipeline of noninvasive assays and drive toward commercialization,” said Mark McDonough, President and CEO of OncoCell MDx. “Christopher is a proven commercial operator with an impressive record of leading successful product launches, both domestically and internationally. He has an outstanding reputation within the molecular diagnostics industry, and especially within the urology community, where we will launch our first immunogenomics test for prostate cancer.”
Christopher has more than 25 years of successful commercial operations experience. He most recently served as Chief Operating Officer for MDxHealth, a publicly traded multi-national molecular diagnostics company that specializes in epigenetic testing solutions for urologic oncology. He was responsible for establishing the company’s commercial operations and led the team that developed, validated and launched the company’s first prostate cancer test. Chris led initiatives to navigate the MolDX program to capture Medicare coverage, gain NCCN Guideline inclusion, obtain a unique CPT billing code, and secure broad reimbursement coverage while driving market adoption with over 4,000 urologists across the US. Previously, Christopher held various leadership positions at Agendia, Numira Biosciences, US LABS (LabCorp) and Ventana Medical Systems (Roche).
“OncoCell has developed a unique non-invasive assay leveraging an immunogenomics platform developed at Harvard Medical School that has potential to significantly improve the way cancer and neuro degenerative disease is managed. I am excited to join the team in addressing a significant unmet need for oncologists, urologists and their patients,” stated Christopher Thibodeau. “In prostate cancer, where there is ongoing controversy on prostate cancer screening and overtreatment, Active Surveillance is one of the fastest growing patient management pathways for men with early stage disease. Unfortunately, monitoring tools available to urologists today carry a high cost, morbidity and leave patients at risk for disease progression. OncoCell’s proprietary noninvasive blood test, which can be used to set a baseline and then monitor patients annually, will help urologists improve patient care and overall outcomes.”
OncoCell MDx is a privately held company developing and commercializing novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. The company’s noninvasive blood-based immunogenomic assays are designed to aid physicians to better understand underlying disease pathology in prostate cancer and other oncology and non-oncology indications. For more information about OncoCell MDx and its technology, visit: https://oncocellmdx.com/.